Let’s start up with the current stock price of Intellia Therapeutics Inc. (NTLA), which is $76.35 to be very precise. The Stock rose vividly during the last session to $78.17 after opening rate of $71.72 while the lowest price it went was recorded $71.5145 before closing at $70.79.
Recently in News on April 12, 2021, Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors. Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Georgia Keresty, Ph.D., M.P.H., to the company’s Board of Directors. You can read further details here
Intellia Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $92.00 on 01/15/21, with the lowest value was $43.86 for the same time period, recorded on 03/05/21.
Intellia Therapeutics Inc. (NTLA) full year performance was 478.41%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Intellia Therapeutics Inc. shares are logging -17.01% during the 52-week period from high price, and 519.72% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $12.32 and $92.00.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1342638 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Intellia Therapeutics Inc. (NTLA) recorded performance in the market was 40.35%, having the revenues showcasing 0.87% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 5.35B, as it employees total of 312 workers.
Analysts verdict on Intellia Therapeutics Inc. (NTLA)
During the last month, 0 analysts gave the Intellia Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 62.12, with a change in the price was noted +41.51. In a similar fashion, Intellia Therapeutics Inc. posted a movement of +119.14% for the period of last 100 days, recording 1,643,100 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for NTLA is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Intellia Therapeutics Inc. (NTLA): Technical Analysis
Raw Stochastic average of Intellia Therapeutics Inc. in the period of last 50 days is set at 77.28%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 69.98%. In the last 20 days, the company’s Stochastic %K was 55.83% and its Stochastic %D was recorded 52.64%.
Let’s take a glance in the erstwhile performances of Intellia Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 40.35%. Additionally, trading for the stock in the period of the last six months notably improved by 219.32%, alongside a boost of 478.41% for the period of the last 12 months. The shares increased approximately by 7.40% in the 7-day charts and went down by 12.18% in the period of the last 30 days. Common stock shares were driven by 0.87% during last recorded quarter.